These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 33559307)

  • 21. Clinicopathological characteristics predict lymph node metastases in ypT0-2 rectal cancer after chemoradiotherapy.
    Bosch SL; Vermeer TA; West NP; Swellengrebel HA; Marijnen CA; Cats A; Verhoef C; van Lijnschoten I; de Wilt JH; Rutten HJ; Nagtegaal ID
    Histopathology; 2016 Nov; 69(5):839-848. PubMed ID: 27270756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic analysis of rectal cancer patients after neoadjuvant chemoradiotherapy: different prognostic factors in patients with different TRGs.
    Tang YL; Li DD; Duan JY; Wang X
    Int J Colorectal Dis; 2024 Jun; 39(1):93. PubMed ID: 38896374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The combination of early treatment response and ypT stage is a novel metric to stage rectal cancer patients treated with neoadjuvant chemoradiotherapy.
    Cui J; Yang L; Guo L; Shao Y; Tan D; Li N; Zhang H
    Oncotarget; 2017 Jun; 8(23):37845-37854. PubMed ID: 28103579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T-stage downstaging of locally advanced rectal cancer after neoadjuvant chemoradiotherapy is not associated with reduced recurrence after adjusting for tumour characteristics.
    Hayes IP; Milanzi E; Pelly RM; Gibbs P; Reece JC
    J Surg Oncol; 2022 Sep; 126(4):728-739. PubMed ID: 35635190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prognosis and complications of local excision for rectal cancer after neoadjuvant chemoradiotherapy].
    Li YH; Qiu XY; Lin GL; Zhou JL; Xiao Y; Qiu HZ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Apr; 24(4):344-351. PubMed ID: 33878824
    [No Abstract]   [Full Text] [Related]  

  • 26. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].
    Wu T; Wen L; Zhang J; Wu Y; Jiang Y; Chen G; Wang X; Huang S; Wan Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):59-65. PubMed ID: 30703795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy.
    Koo T; Song C; Kim JS; Kim K; Chie EK; Kang SB; Lee KW; Kim JH; Jeong SY; Kim TY
    PLoS One; 2015; 10(9):e0138728. PubMed ID: 26381522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01).
    Yeo SG; Kim DY; Kim TH; Chang HJ; Oh JH; Park W; Choi DH; Nam H; Kim JS; Cho MJ; Kim JH; Park JH; Kang MK; Koom WS; Kim JS; Nam TK; Chie EK; Kim JS; Lee KJ
    Ann Surg; 2010 Dec; 252(6):998-1004. PubMed ID: 21107110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant chemoradiotherapy affects the indications for lateral pelvic node dissection in mid/low rectal cancer with clinically suspected lateral node involvement: a multicenter retrospective cohort study.
    Oh HK; Kang SB; Lee SM; Lee SY; Ihn MH; Kim DW; Park JH; Kim YH; Lee KH; Kim JS; Kim JW; Kim JH; Chang TY; Park SC; Sohn DK; Oh JH; Park JW; Ryoo SB; Jeong SY; Park KJ
    Ann Surg Oncol; 2014 Jul; 21(7):2280-7. PubMed ID: 24604580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can clinicopathological parameters predict for lymph node metastases in ypT0-2 rectal carcinoma? Results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 trials.
    von den Grün JM; Hartmann A; Fietkau R; Ghadimi M; Liersch T; Hohenberger W; Weitz J; Sauer R; Wittekind C; Ströbel P; Rödel C; Fokas E;
    Radiother Oncol; 2018 Sep; 128(3):557-563. PubMed ID: 29929861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nodal Disease in Rectal Cancer Patients With Complete Tumor Response After Neoadjuvant Chemoradiation: Danger Below Calm Waters.
    Baucom RB; Maguire LH; Kavalukas SL; Geiger TM; Ford MM; Muldoon RL; Hopkins MB; Hawkins AT
    Dis Colon Rectum; 2017 Dec; 60(12):1260-1266. PubMed ID: 29112561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of metastatic lymph node regression grade after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
    Tominaga T; Akiyoshi T; Yamamoto N; Oba K; Nagasaki T; Yamaguchi T; Konishi T; Fukunaga Y; Ueno M
    Surgery; 2019 Dec; 166(6):1061-1067. PubMed ID: 31345564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poorer Oncologic Outcome of Good Responders to PCRT With Remnant Lymph Nodes Defies the Oncologic Paradox in Patients With Rectal Cancer.
    Cho E; Park IJ; Hong SM; Lee JL; Kim CW; Yoon YS; Lim SB; Yu CS; Kim JC
    Clin Colorectal Cancer; 2019 Jun; 18(2):e171-e178. PubMed ID: 31027968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Long-term prognostic analysis on complete/near-complete clinical remission for mid-low rectal cancer after neoadjuvant chemoradiotherapy].
    Wang L; Li S; Zhang X; Sun T; Du C; Chen N; Peng Y; Yao Y; Zhan T; Zhao J; Cai Y; Li Y; Wang W; Li Z; Sun Y; Ji J; Wu A
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1240-1248. PubMed ID: 30506534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Impact of Preoperative Albumin-Globulin Ratio in Patients with Rectal Cancer Treated with Preoperative Chemoradiotherapy.
    Toiyama Y; Oki S; Okugawa Y; Ide S; Yasuda H; Fujikawa H; Yoshiyama S; Hiro J; Ohi M; Inoue Y; Araki T; Kusunoki M
    Oncology; 2018; 95(5):270-280. PubMed ID: 29996133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A single center retrospective study on surgical efficacy of T3NxM0 middle-low rectal cancer without neoadjuvant therapy].
    Liu P; Lou Z; Mei Z; Gao X; Hao L; Liu L; Gong H; Meng R; Yu E; Wang H; Wang H; Zhang W
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):66-72. PubMed ID: 30703796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for local recurrence following neoadjuvant chemoradiotherapy for rectal cancers.
    Peng JY; Li ZN; Wang Y
    World J Gastroenterol; 2013 Aug; 19(32):5227-37. PubMed ID: 23983425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center.
    Zhou J; Qiu H; Lin G; Xiao Y; Wu B; Wu W; Sun X; Lu J; Zhang G; Xu L; Liu Y
    Int J Colorectal Dis; 2016 Jun; 31(6):1163-8. PubMed ID: 27044403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of neoadjuvant therapy on nodal harvest in clinical stage III rectal cancer: Establishing optimum cut-offs by disease response.
    Wehrle CJ; Woo K; Chang J; Gamaleldin M; DeHaan R; Dahdaleh F; Felder S; Rosen DR; Champagne B; Steele SR; Naffouje SA
    J Surg Oncol; 2024 Apr; 129(5):945-952. PubMed ID: 38221655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MRI-detected tumor deposits in cT3 and cT4 rectal cancer following neoadjuvant chemoradiotherapy.
    Que YT; Chen Y; Yang XY; Ma YR; Liu YY; Wen ZQ; Lu BL; Wu XH; Zhang ZW; Wu YZ; Yu SP; Yuan JP
    Eur Radiol; 2024 May; 34(5):2963-2973. PubMed ID: 37840101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.